Pazopanib Maintenance Phase II

Inclusion Criteria: * Subjects must provide written informed consent prior to performance of study-specific procedures or assessments and must be willing to comply with treatment and follow up * Patients must have histological evidence of high-grade soft tissue sarcoma (grade 2 - 3) according to the FNLCC grading system, tumor size ≥ 5 cm and deep localization with regard to the superficial fascia, excluding the following tumor types: * Embryonal rhabdomyosarcoma * Chondrosarcoma (excluding extraskeletal myxoid chondrosarcoma) * Osteosarcoma (excluding extraskeletal osteosarcoma) * Ewing tumors / primitive neuroectodermal tumor (PNET) * Gastro-intestinal stromal tumors (GIST) * Dermatofibrosarcoma protuberans * Patients who had undergone previous surgery with inadequate margins (tumour-free margins ≤1 cm or margins contaminated) are eligible if thermochemotherapy has been started within 8 weeks after surgery * Unstained slides and ideally tumour blocks must be available for histological central review * Completed 4 to 8 cycles of thermochemotherapy with doxorubicin and ifosfamide at least 21 days but no more than 42 days prior to study entry * No evidence of disease following completion of first-line thermochemotherapy and within ≤ 21 days of study entry * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * No other prior chemotherapy except thermochemotherapy with doxorubicin and ifosfamide * Adequate organ system function Exclusion Criter…